As frustrations mount over the need for, what seems never ending, boosters. The emphasis will continue to lean toward therapeutics, and IP will be provided grant money in 2022. Either domestically or from abroad.
That’s my prediction.
(2)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links